Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

GlycoMimetics, Inc. (GLYC)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.8400-0.1000 (-5.15%)
At close: 4:00PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.9400
Open1.8800
Bid1.9000 x 2900
Ask1.9500 x 3100
Day's Range1.8300 - 1.9200
52 Week Range1.7200 - 4.4000
Volume395,405
Avg. Volume686,453
Market Cap94.832M
Beta (5Y Monthly)2.12
PE Ratio (TTM)N/A
EPS (TTM)-1.2130
Earnings DateNov 04, 2021 - Nov 08, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.67
  • Business Wire

    GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

    ROCKVILLE, Md., November 25, 2021--GlycoMimetics, Inc. (the "Company") (NASDAQ:GLYC) today announced that the compensation committee of the Company’s Board of Directors approved the grant on November 22, 2021 of a non-qualified stock option award to purchase an aggregate of 100,000 shares to one new employee. The award was granted as an inducement equity award outside of the Company’s 2013 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4), and was made as an inducement mate

  • Business Wire

    Apollomics Inc. Doses First Patient in Phase 3 Clinical Trial in China of GlycoMimetics’ Uproleselan for the Treatment of AML

    ROCKVILLE, Md., November 23, 2021--GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that Apollomics has dosed the first patient in China in a Phase 3 clinical trial of APL-106 (uproleselan injection) for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML). Apollomics’ Phase 3 trial with APL-106 is part of the overall development program for Apollomics in China that also includes an ongoing Phase 1 pharmacokinetics (PK) and tolerability study. The Phase 3 clinical t

  • Business Wire

    GlycoMimetics Appoints Regulatory Veteran Lisa DeLuca as Vice President, Regulatory Affairs

    ROCKVILLE, Md., November 22, 2021--GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that Lisa DeLuca, Ph.D., has joined its executive leadership team as Vice President, Regulatory Affairs. Dr. DeLuca is a veteran regulatory expert who has previously led the strategy-formation and execution of multiple global NDA submissions and product registrations. Most recently she was the head of regulatory affairs at Nuvation Bio and a member of its executive leadership team.

Advertisement
Advertisement